Subgroup analysis based on ethnicity showed that MMP-1-1607 1G/2G polymorphism decreased the risk of prostate cancer among Caucasians under 2G vs. 1G model (OR = 0.54, 95% CI = 0.32–0.90) and 2G/2G vs. 1G/1G+1G/2G model (OR = 0.42, 95% CI = 0.19–0.91). Here, MMP1 is linked to prostate carcinoma.